Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Sarcoma 1

Conditions

Sarcoma 11Gliosarcoma 6Glioblastoma 6Central Nervous System Neoplasms 6Brain Neoplasms 5Rhabdomyosarcoma 2Recurrence 2Osteosarcoma 2Gastrointestinal Stromal Tumors 2Bone Neoplasms 2Stomach Neoplasms 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Prostatic Neoplasms 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Glioma 1Digestive System Neoplasms 1Chondrosarcoma 1Astrocytoma 1Advanced Solid Tumors 1

Interventions

Imatinib Mesylate 3repotrectinib 1fludarabine 1alectinib 1Stem Cell Transplantation 1Sirolimus 1Melphalan 1Everolimus 1E-7386 1Busulfan 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Digestive System Neoplasms × Everolimus × Sarcoma × Clear all
NCT01275222 2021-06-25

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

Novartis

Phase 1/2 Completed
117 enrolled 18 charts
GastrointestinalSarcoma

Digestive System Neoplasms, Sarcoma, Stomach Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡